Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axatilimab + extracorporeal photopheresis
- Development stage
- Unknown
- Lead developer
- Syndax Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Extracorporeal
01
Overview
Axatilimab (Niktimvo) is a humanized IgG4 monoclonal antibody that targets the colony-stimulating factor 1 receptor (CSF-1R). By inhibiting CSF-1R signaling, it depletes profibrotic macrophages and monocytes that drive inflammation and tissue damage in chronic graft-versus-host disease (cGVHD). The University of Miami is investigating axatilimab in combination with extracorporeal photopheresis (ECP), an immunomodulatory procedure where blood is treated with a photosensitizing agent and UVA light, to enhance therapeutic outcomes in patients with refractory cGVHD. This combination therapy aims to provide a synergistic effect by targeting different pathways of the immune-mediated fibrotic process characteristic of the disease.
- Brand names
- Niktimvo
- Other names
- AxatilimabExtracorporeal PhotopheresisECP
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on axatilimab + extracorporeal photopheresis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axatilimab + extracorporeal photopheresis.